MURICIN

Main information

  • Trade name:
  • MURICIN- mupirocin ointment
  • Composition:
  • MUPIROCIN 20 mg in 1 g
  • Administration route:
  • TOPICAL
  • Prescription type:
  • PRESCRIPTION
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • MURICIN- mupirocin ointment
    United States
  • Language:
  • English

Therapeutic information

  • Therapeutic indications:
  • Muricin® ointment is indicated for the topical treatment of canine bacterial infections of the skin, including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and Staphylococcus intermedius.

Status

  • Source:
  • DailyMed - NLM - National Library of Medicine
  • Authorization status:
  • Abbreviated New Animal Drug Application
  • Authorization number:
  • 17033-420-15
  • Last update:
  • 05-06-2019

Summary of Product characteristics: dosage, interactions, side effects

MURICIN- mupirocin ointment

Dechra Veterinary Products

----------

MURICIN

mupirocin

ointment 2%

ANADA# 200-418. Approved by FDA.

For dermatologic use on dogs.

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

Each gram of Muricin ointment contains 20 mg of mupirocin in a bland, water-washable ointment base

consisting of polyethylene glycol 400 and polyethylene glycol 3350 (polyethylene glycol ointment,

NF). Mupirocin is a naturally-occurring, broadspectrum antibiotic. The chemical name is (E)-

(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-

methyl-2H-pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid. The chemical structure is:

CLINICAL PHARMACOLOGY:

Mupirocin is a chemical entity produced by fermentation of the organism Pseudomonas fluorescens.

Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial

isoleucyl transfer-RNA synthetase. Due to this mode of action, mupirocin shows no cross resistance

with chloramphenicol, erythromycin, gentamicin, lincomycin, neomycin, novobiocin, penicillin,

streptomycin, and tetracycline. Mupirocin is an antimicrobial agent that inhibits the growth of gram-

positive and gram-negative bacteria. Bacteria susceptible to the action of mupirocin in vitro include the

aerobic isolates of Staphylococcus aureus (including methicillin-resistant strains and β-lactamase-

producing strains), Staphylococcus intermedius, Staphylococcus epidermidis, other coagulase positive or

negative Staphylococci, α-hemolytic Streptococci, β group A Streptococci (including S. pyogenes),

other β Streptococci (including S. agalactiae), group D Streptococci (including S. faecalis and S.

faecium), group Viridans Streptococci, Streptococcus pneumoniae, Corynebacterium hofmanii, Bacillus

subtilis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae,

Enterobacter aerogenes, Citrobacter freundii, Hemophilus influenzae (including β-lactamase-producing

strains), Neisseria gonorrheae (including β-lactamase-producing strains), Neisseria meningitidis,

Branhamella catarrhalis and Pasteurella multocida, and the anaerobic isolates of Peptostreptococcus

anaerobius, Clostridium difficile, and Clostridium sporogenes.

®

Clinical significance of the in vitro data is unknown except for susceptible strains of Staphylococcus

aureus and Staphylococcus intermedius.

INDICATIONS FOR USE:

Muricin ointment is indicated for the topical treatment of canine bacterial infections of the skin,

including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and

Staphylococcus intermedius.

CONTRAINDICATIONS:

WARNINGS:

ADVERSE REACTIONS:

DOSAGE AND ADMINISTRATION:

HOW SUPPLIED:

1. Remove entire Applicator Assembly, puncture tube with white portion of the cap.

This drug is contraindicated in animals with a history of sensitivity reactions to any of its

components.

Because of the potential hazard of nephrotoxicity due to the polyethylene glycol content of the

base, care should be exercised when using this product in treating extensive deep lesions where

absorption of large quantities of polyethylene glycol is possible.

Safety of use in pregnant or breeding animals has not been determined. Muricin ointment is not

for ophthalmic use.

No adverse reactions have been reported with this product. If a skin reaction such as irritation

should occur, treatment should be discontinued and appropriate therapy instituted.

Prior to treatment, the lesion should be cleansed. Muricin ointment should be applied to the

affected area twice a day. Apply a sufficient amount of ointment to completely cover the infected

area. Maximum duration of treatment should not exceed 30 days.

Muricin Ointment is supplied in 15-gram tubes.

NDC 17033-420-15.

Store between 15° and 30°C (59° and 86°F).

Keep Out of Reach of Children

2. Replace entire Applicator Assembly.

3. To dispense, remove the white portion of the cap.

4. After use replace white cap to close.

IMPORTANT:

The opening of this product is covered by a metal tamper-resistant seal.

If this seal has been punctured or is not visible, do not use and return product to place of purchase.

MANUFACTURED FOR:

Dechra Veterinary Products

Overland Park, KS 66211

I420 DECHRA R1/08 #131

PRINCIPAL DISPLAY PANEL - 15 g Carton

MURICIN

mupirocin ointment 2%

®

For dermatologic use on dogs

NET WT 15 g

ANADA # 200-418. Approved by FDA.

NDC 17033-420-15

PRINCIPAL DISPLAY PANEL - 15 g Container

NET WT 15g

MURICIN

mupirocin

ointment 2 %

For dermatologic use on dogs

NDC 17033-420-15

ANADA #200-418.

Approved by FDA.

®

MURICIN

mupirocin ointment

Product Information

Product T ype

PRESCRIPTION ANIMAL DRUG

Ite m Code (Source )

NDC:170 33-420

Route of Administration

TOPICAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

MUPIRO CIN (UNII: D0 GX8 6 3OA5) (MUPIROCIN - UNII:D0 GX8 6 3OA5)

MUPIROCIN

20 mg in 1 g

Inactive Ingredients

Ingredient Name

Stre ng th

PO LYETHYLENE GLYCO L 3 3 50 (UNII: G2M7P15E5P)

PO LYETHYLENE GLYCO L 4 0 0 (UNII: B6 9 78 9 4SGQ)

Packag ing

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:170 33-420 -15

1 in 1 CARTON

1

15 g in 1 TUBE

Dechra Veterinary Products

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANADA

ANADA20 0 418

0 3/0 8 /20 0 7

Labeler -

Dechra Veterinary Products (362142734)

Registrant -

Fougera Pharmaceuticals Inc. (043838424)

Revised: 3/2018